Soleno Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Soleno Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||||
| current assets | ||||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 76,497,000 | 81,331,000 | 87,928,000 | 48,413,000 | 57,024,000 | 42,847,000 | 169,681,000 | 52,437,000 | 19,368,000 | 7,874,000 | 14,602,000 | 19,751,000 | 24,065,000 | 28,974,000 | 21,304,000 | 28,185,000 | 33,596,000 | 41,607,000 | 49,224,000 | 56,137,000 | 62,499,000 | 15,070,000 | 20,733,000 | 11,225,000 | 15,503,000 | 19,402,000 | 23,099,000 | 10,239,000 | 12,593,000 | 14,866,000 | 17,099,507 | 5,647,000 | 7,547,000 | 10,539,000 | 2,725,996 | 5,415,000 | 2,502,000 | 6,492,000 | 5,494,523 | 4,720,000 | 7,530,000 | 9,529,000 | 7,956,710 | 64,000 |
| marketable securities | 210,344,000 | 208,619,000 | 203,509,000 | 208,363,000 | 209,099,000 | |||||||||||||||||||||||||||||||||||||||
| accounts receivable | 24,624,000 | 3,000 | 110,000 | 133,337 | 137,000 | 288,000 | 187,000 | 156,127 | 94,000 | 12,000 | 8,000 | 37,000 | ||||||||||||||||||||||||||||||||
| inventory | 2,355,000 | 164,000 | 855,000 | 660,391 | 703,000 | 774,000 | 653,000 | 551,008 | 376,000 | 277,000 | 206,000 | 109,336 | ||||||||||||||||||||||||||||||||
| prepaid expenses and other current assets | 2,969,000 | 18,965,000 | 2,452,000 | 1,423,000 | 1,379,000 | 1,596,000 | 1,677,000 | 1,222,000 | 1,130,000 | 1,253,000 | 1,045,000 | 821,000 | 824,000 | 1,004,000 | 1,118,000 | 702,000 | 948,000 | 921,000 | 1,019,000 | 348,000 | 505,000 | 572,000 | 411,000 | 375,000 | 471,000 | 603,000 | 529,000 | 327,000 | 248,000 | 423,000 | 342,927 | 145,000 | 246,000 | 261,000 | 246,570 | 217,000 | 157,000 | 216,000 | 167,642 | 225,000 | 311,000 | 260,000 | 252,272 | 186,000 |
| total current assets | 316,789,000 | 308,915,000 | 293,889,000 | 258,199,000 | 267,502,000 | 151,223,000 | 171,358,000 | 53,659,000 | 20,498,000 | 9,127,000 | 15,647,000 | 20,572,000 | 24,889,000 | 29,978,000 | 22,422,000 | 28,887,000 | 34,544,000 | 42,528,000 | 50,243,000 | 56,485,000 | 63,004,000 | 15,642,000 | 21,144,000 | 11,609,000 | 16,615,000 | 20,865,000 | 24,670,000 | 11,413,000 | 13,311,000 | 15,808,000 | 17,993,807 | 6,390,000 | 10,318,000 | 11,800,000 | 3,801,294 | 6,507,000 | 3,756,000 | 7,583,000 | 6,404,300 | 5,526,000 | 8,165,000 | 10,023,000 | 8,338,318 | 307,000 |
| long-term assets | ||||||||||||||||||||||||||||||||||||||||||||
| property and equipment | 166,000 | 173,000 | 186,000 | 196,000 | 19,000 | 27,000 | 12,000 | 15,000 | 19,000 | 22,000 | 26,000 | 23,000 | 28,000 | 27,000 | 33,000 | 26,000 | 27,000 | 20,000 | 19,000 | 20,000 | 17,000 | 19,000 | 22,000 | 46,000 | 22,000 | 19,000 | 12,000 | 14,000 | 13,000 | 17,000 | 22,885 | 55,000 | 53,000 | 93,000 | 102,560 | 116,000 | 118,000 | 121,000 | 85,745 | 98,000 | 43,000 | 44,000 | 57,607 | 36,000 |
| operating lease right-of-use assets | 2,434,000 | 2,603,000 | 2,798,000 | 2,992,000 | 268,000 | 338,000 | 407,000 | 474,000 | 541,000 | 53,000 | 131,000 | 206,000 | 279,000 | 350,000 | 421,000 | 489,000 | 558,000 | 50,000 | 124,000 | 195,000 | 265,000 | 332,000 | 398,000 | |||||||||||||||||||||
| intangible assets | 5,832,000 | 6,318,000 | 6,805,000 | 7,291,000 | 7,777,000 | 8,263,000 | 8,749,000 | 9,235,000 | 9,721,000 | 10,207,000 | 10,693,000 | 11,178,000 | 11,665,000 | 12,151,000 | 12,637,000 | 13,123,000 | 13,609,000 | 14,095,000 | 14,581,000 | 15,067,000 | 15,553,000 | 16,039,000 | 16,525,000 | 17,011,000 | 17,497,000 | 17,983,000 | 18,469,000 | 18,955,000 | 19,441,000 | 19,927,000 | 20,413,056 | |||||||||||||
| long-term marketable securities | 7,002,000 | 27,211,000 | 27,945,000 | 28,482,000 | ||||||||||||||||||||||||||||||||||||||||
| other long-term assets | 83,000 | 83,000 | 83,000 | 83,000 | 83,000 | 165,000 | 165,000 | 165,000 | 165,000 | 126,000 | 40,000 | 40,000 | 40,000 | 40,000 | 59,000 | 59,000 | 59,000 | |||||||||||||||||||||||||||
| total assets | 332,306,000 | 318,092,000 | 330,972,000 | 296,706,000 | 304,131,000 | 168,837,000 | 180,691,000 | 63,548,000 | 30,944,000 | 19,535,000 | 26,497,000 | 31,979,000 | 36,861,000 | 42,546,000 | 35,553,000 | 42,565,000 | 48,778,000 | 56,706,000 | 64,982,000 | 71,784,000 | 78,859,000 | 32,113,000 | 38,172,000 | 28,725,000 | 34,134,000 | 38,867,000 | 43,151,000 | 30,835,000 | 33,344,000 | 36,331,000 | 39,021,665 | 26,382,000 | 30,381,000 | 33,865,000 | 5,564,852 | 8,309,000 | 5,535,000 | 9,390,000 | 8,201,195 | 7,288,000 | 8,770,000 | 10,067,000 | 8,395,925 | 1,696,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||
| current liabilities | ||||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 6,216,000 | 5,483,000 | 8,882,000 | 6,243,000 | 3,716,000 | 8,022,000 | 3,149,000 | 3,216,000 | 3,442,000 | 2,778,000 | 1,777,000 | 2,324,000 | 2,406,000 | 2,411,000 | 3,254,000 | 3,858,000 | 3,348,000 | 4,669,000 | 3,489,000 | 3,213,000 | 3,657,000 | 3,480,000 | 1,995,000 | 1,735,000 | 1,740,000 | 1,258,000 | 934,000 | 1,245,000 | 981,000 | 1,133,000 | 633,104 | 642,000 | 1,029,000 | 935,000 | 537,891 | 862,000 | 957,000 | 1,262,000 | 695,056 | 953,000 | 989,000 | 621,000 | 986,799 | 1,238,000 |
| accrued compensation | 6,267,000 | 4,277,000 | 4,776,000 | 3,408,000 | 2,149,000 | 1,226,000 | 3,135,000 | 1,498,000 | 1,165,000 | 721,000 | 1,675,000 | 1,282,000 | 932,000 | 598,000 | 728,000 | 809,000 | 652,000 | 411,000 | 1,005,000 | 756,000 | 520,000 | 338,000 | 283,000 | |||||||||||||||||||||
| accrued clinical trial site costs | 1,863,000 | 1,824,000 | 1,826,000 | 1,762,000 | 1,863,000 | 2,395,000 | 3,393,000 | 3,237,000 | 3,466,000 | 3,531,000 | 3,222,000 | 2,826,000 | 3,156,000 | 3,521,000 | 3,420,000 | 3,593,000 | 3,927,000 | 4,140,000 | 3,789,000 | 3,399,000 | 3,444,000 | 2,846,000 | 1,999,000 | |||||||||||||||||||||
| operating lease liabilities | 676,000 | 597,000 | 526,000 | 448,000 | 296,000 | 310,000 | 273,000 | 39,000 | 155,000 | 239,000 | 337,000 | 344,000 | 282,000 | 290,000 | 180,000 | 57,000 | 139,000 | 220,000 | 298,000 | 315,000 | 305,000 | |||||||||||||||||||||||
| accrued interest payable | 409,000 | 423,000 | ||||||||||||||||||||||||||||||||||||||||||
| other current liabilities | 5,512,000 | 3,127,000 | 2,737,000 | 3,101,000 | 1,126,000 | 1,511,000 | 1,555,000 | 848,000 | 513,000 | 692,000 | 484,000 | 671,000 | 415,000 | 439,000 | 323,000 | 492,000 | 255,000 | 232,000 | 196,000 | 408,000 | 444,000 | 308,000 | 382,000 | |||||||||||||||||||||
| total current liabilities | 20,943,000 | 15,731,000 | 18,747,000 | 14,962,000 | 9,150,000 | 13,464,000 | 11,505,000 | 28,993,000 | 8,798,000 | 7,761,000 | 7,313,000 | 7,342,000 | 7,246,000 | 7,313,000 | 8,007,000 | 9,042,000 | 8,362,000 | 9,509,000 | 8,618,000 | 7,996,000 | 8,363,000 | 7,287,000 | 4,964,000 | 3,454,000 | 2,855,000 | 2,250,000 | 1,877,000 | 2,508,000 | 1,945,000 | 1,942,000 | 1,732,769 | 1,731,000 | 2,122,000 | 2,172,000 | 1,707,378 | 1,777,000 | 1,901,000 | 2,579,000 | 3,192,735 | 6,028,000 | 13,349,000 | 1,059,000 | 1,289,785 | 1,596,000 |
| long-term liabilities | ||||||||||||||||||||||||||||||||||||||||||||
| contingent liability for essentialis purchase price | 18,859,000 | 17,758,000 | 14,791,000 | 14,464,000 | 13,587,000 | 11,950,000 | 11,549,000 | 10,468,000 | 9,447,000 | 9,134,000 | 8,835,000 | 9,437,000 | 9,305,000 | 8,689,000 | 9,547,000 | 12,876,000 | 12,325,000 | 9,291,000 | 10,278,000 | 10,138,000 | 9,364,000 | 6,522,000 | 5,938,000 | 6,066,000 | 6,038,000 | 5,855,000 | 5,649,000 | 5,671,000 | 5,443,000 | 5,510,000 | 5,081,840 | |||||||||||||
| long-term debt | 49,845,000 | 49,836,000 | 49,828,000 | |||||||||||||||||||||||||||||||||||||||||
| long-term lease liabilities | 2,248,000 | 2,361,000 | 2,472,000 | 2,581,000 | 37,000 | 130,000 | 79,000 | 175,000 | ||||||||||||||||||||||||||||||||||||
| other long-term liabilities | 271,000 | 145,000 | 21,000 | 60,000 | 147,000 | 38,000 | 1,132,000 | 1,132,000 | 1,201,000 | 196,000 | 200,000 | 200,000 | ||||||||||||||||||||||||||||||||
| total liabilities | 92,166,000 | 85,831,000 | 85,859,000 | 32,007,000 | 23,374,000 | 25,451,000 | 23,184,000 | 40,328,000 | 18,518,000 | 16,896,000 | 16,149,000 | 16,779,000 | 16,553,000 | 16,085,000 | 17,760,000 | 22,362,000 | 21,341,000 | 19,138,000 | 19,435,000 | 23,778,000 | 22,682,000 | 22,632,000 | 23,225,000 | 13,840,000 | 20,291,000 | 15,236,000 | 12,738,000 | 16,630,000 | 17,507,000 | 13,312,000 | 12,486,757 | 3,172,000 | 3,693,000 | 3,721,000 | 2,129,655 | 8,579,000 | 16,402,000 | 21,370,000 | ||||||
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding | ||||||||||||||||||||||||||||||||||||||||||||
| common stock | 50,000 | 49,000 | 46,000 | 41,000 | 38,000 | 33,000 | 32,000 | 15,000 | 10,000 | 8,000 | 8,000 | 8,000 | 120,000 | 120,000 | 80,000 | 80,000 | 80,000 | 80,000 | 80,000 | 80,000 | 80,000 | 45,000 | 45,000 | 32,000 | 32,000 | 32,000 | 32,000 | 21,000 | 21,000 | 20,000 | 19,239 | 10,000 | 48,000 | 47,000 | 16,786 | 15,000 | 15,000 | 15,000 | 14,018 | 12,000 | 8,000 | 7,000 | 6,769 | 1,000 |
| additional paid-in-capital | 740,746,000 | 728,019,000 | 696,966,000 | 660,041,000 | 600,534,000 | 441,267,000 | 433,885,000 | 288,320,000 | 266,669,000 | 248,393,000 | 247,762,000 | 247,130,000 | 245,993,000 | 245,422,000 | 231,068,000 | 230,650,000 | 229,744,000 | 228,887,000 | 227,912,000 | 227,519,000 | 227,145,000 | 173,100,000 | 172,708,000 | 158,034,000 | 157,881,000 | 157,661,000 | 157,413,000 | 141,479,000 | 141,187,000 | 140,733,000 | 140,494,976 | 132,154,000 | 131,807,000 | 131,296,000 | 101,730,285 | 101,395,000 | 95,543,000 | 95,255,000 | 89,456,466 | 82,099,000 | 72,469,000 | 70,679,000 | 60,635,664 | 20,741,000 |
| accumulated other comprehensive income | 85,000 | 16,000 | ||||||||||||||||||||||||||||||||||||||||||
| accumulated deficit | -500,741,000 | -496,033,000 | -452,260,000 | -396,278,000 | -319,662,000 | -297,808,000 | -276,410,000 | -265,114,000 | -254,253,000 | -245,778,000 | -237,422,000 | -231,936,000 | -225,804,000 | -219,079,000 | -213,355,000 | -210,527,000 | -202,387,000 | -191,399,000 | -182,445,000 | -179,593,000 | -171,048,000 | -163,664,000 | -157,806,000 | -143,181,000 | -144,070,000 | -134,062,000 | -127,032,000 | -127,295,000 | -125,371,000 | -117,734,000 | -113,979,312 | -108,954,000 | -105,167,000 | -101,199,000 | -98,311,887 | -95,698,000 | -92,948,000 | -89,436,000 | -86,246,673 | -83,402,000 | -80,109,000 | -81,989,000 | -70,975,024 | -63,120,000 |
| total stockholders’ equity | 240,140,000 | 232,261,000 | 245,113,000 | 264,699,000 | 280,757,000 | 143,386,000 | 157,507,000 | 23,220,000 | 12,426,000 | 2,639,000 | 10,348,000 | 15,200,000 | 20,308,000 | 26,461,000 | 17,793,000 | 20,203,000 | 27,437,000 | 37,568,000 | 45,547,000 | 48,006,000 | 56,177,000 | 9,481,000 | 14,947,000 | 14,885,000 | 13,843,000 | 23,631,000 | 30,413,000 | 14,205,000 | 15,837,000 | 23,019,000 | 26,534,908 | 23,210,000 | 26,688,000 | 30,144,000 | 3,435,197 | 5,712,000 | 2,610,000 | 5,834,000 | 3,223,816 | |||||
| total liabilities and stockholders’ equity | 332,306,000 | 318,092,000 | 330,972,000 | 296,706,000 | 304,131,000 | 168,837,000 | 180,691,000 | 63,548,000 | 30,944,000 | 19,535,000 | 26,497,000 | 31,979,000 | 36,861,000 | 42,546,000 | 35,553,000 | 42,565,000 | 48,778,000 | 56,706,000 | 64,982,000 | 71,784,000 | 78,859,000 | 32,113,000 | 38,172,000 | 28,725,000 | 34,134,000 | 38,867,000 | 43,151,000 | 30,835,000 | 33,344,000 | 36,331,000 | 39,021,665 | 26,382,000 | 30,381,000 | 33,865,000 | 5,564,852 | 8,309,000 | 5,535,000 | 9,390,000 | 8,201,195 | |||||
| accumulated other comprehensive gain | 226,000 | 361,000 | 895,000 | |||||||||||||||||||||||||||||||||||||||||
| common stock purchase liability | 637,000 | 19,938,000 | ||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -153,000 | -106,000 | -1,000 | -2,000 | -1,000 | -2,000 | ||||||||||||||||||||||||||||||||||||||
| short-term investments | 106,780,000 | |||||||||||||||||||||||||||||||||||||||||||
| long-term investments | 8,821,000 | |||||||||||||||||||||||||||||||||||||||||||
| 2018 pipe warrant liability | 653,000 | 1,000 | 1,000 | 2,000 | 4,000 | 31,000 | 170,000 | 282,000 | 338,000 | 539,000 | 867,000 | 725,000 | 1,107,000 | 1,354,000 | 590,000 | 1,145,000 | 784,000 | 600,000 | ||||||||||||||||||||||||||
| operating lease liabilities - current | 256,000 | 212,000 | ||||||||||||||||||||||||||||||||||||||||||
| operating lease liabilities - noncurrent | 214,000 | 273,000 | ||||||||||||||||||||||||||||||||||||||||||
| finance lease right-of-use assets | 13,000 | 15,000 | 17,000 | 20,000 | 22,000 | 24,000 | ||||||||||||||||||||||||||||||||||||||
| operating lease liabilities, net of current | 274,000 | 372,000 | ||||||||||||||||||||||||||||||||||||||||||
| 2017 pipe warrant liability | 4,777,000 | 4,230,000 | 7,656,000 | 10,822,000 | 3,667,000 | 10,202,000 | 6,274,000 | 4,563,000 | 6,641,000 | 8,036,000 | 4,927,000 | 5,076,000 | ||||||||||||||||||||||||||||||||
| due from related party | 9,000 | 18,000 | 72,000 | 64,000 | ||||||||||||||||||||||||||||||||||||||||
| minority interest investment in former subsidiary | 623,000 | 788,000 | 978,000 | |||||||||||||||||||||||||||||||||||||||||
| series a warrant liability | 25,000 | 51,000 | 73,000 | 49,000 | 58,000 | 1,015,000 | 291,000 | 351,713 | 289,000 | 415,000 | 291,000 | 194,048 | 509,000 | 631,000 | 558,000 | 1,212,803 | 1,819,000 | 2,159,000 | 3,582,000 | |||||||||||||||||||||||||
| preferred stock, .001 par value, 10,000,000 shares authorized: | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at december 31, 2019 and december 31, 2018; zero shares issued and outstanding at december 31, 2019 and at december 31, 2018. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| accrued compensation and other current liabilities | 1,719,000 | 1,115,000 | 992,000 | 943,000 | 1,153,000 | 862,000 | 721,000 | 973,054 | 976,000 | 879,000 | 1,237,000 | 1,169,487 | 915,000 | 944,000 | 1,317,000 | 1,632,679 | 1,224,000 | 1,223,000 | 438,000 | 201,457 | ||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at september 30, 2019 and december 31, 2018; zero shares issued and outstanding at september 30, 2019 and at december 31, 2018. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at june 30, 2019 and december 31, 2018; zero shares issued and outstanding at june 30, 2019 and at december 31, 2018. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at march 31, 2019 and december 31, 2018; zero shares issued and outstanding at march 31, 2019 and at december 31, 2018. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| restricted cash | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 35,000 | 111,000 | 35,000 | 20,000 | 20,000 | 20,000 | |||||||||||||||||||||||||||||
| current assets held for sale | 847,000 | 470,000 | 484,000 | 516,373 | 563,000 | 2,323,000 | ||||||||||||||||||||||||||||||||||||||
| other assets | 126,000 | 126,000 | 125,530 | 126,000 | 126,000 | 126,000 | 125,530 | 126,000 | 76,000 | 76,000 | 76,340 | |||||||||||||||||||||||||||||||||
| long-term assets held for sale | 453,000 | 453,000 | 453,000 | 466,387 | 458,000 | |||||||||||||||||||||||||||||||||||||||
| current liabilities held for sale | 110,000 | 102,000 | 88,000 | 126,611 | 113,000 | 214,000 | ||||||||||||||||||||||||||||||||||||||
| series c warrant liability | 2,000 | 5,000 | 4,000 | 5,880 | 20,000 | 24,000 | 57,000 | 85,490 | 115,000 | 193,000 | 219,000 | 462,437 | 581,000 | 894,000 | 2,549,000 | |||||||||||||||||||||||||||||
| other liabilities | 13,000 | 13,000 | 13,163 | 142,739 | 109,404 | 151,000 | ||||||||||||||||||||||||||||||||||||||
| long-term liabilities held for sale | 1,750,000 | 1,050,000 | 625,000 | 225,392 | ||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at december 31, 2018 and december 31, 2017; zero and 4,571 shares issued and outstanding at december 31, 2018 and at december 31, 2017, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized: | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at september 30, 2018 and december 31, 2017; nil and 4,571 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at june 30, 2018 and december 31, 2017; nil and 4,571 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at march 31, 2018 and december 31, 2017; 3,571 and 4,571 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 shares designated at december 31, 2017, and december 31, 2016; 4,571 and 12,780 shares issued and outstanding at december 31, 2017, and at december 31, 2016, respectively. liquidation value of zero. | 5 | |||||||||||||||||||||||||||||||||||||||||||
| other intangible assets | 19,353,000 | 19,884,000 | 21,128,000 | 817,465 | 842,000 | 867,000 | 892,000 | 916,807 | 946,000 | |||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at september 30, 2017 and december 31, 2016; 10,049 and 12,780 shares issued and outstanding at september 30, 2017 and at december 31, 2016, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at june 30, 2017 and december 31, 2016; 12,179 and 12,780 shares issued and outstanding at june 30, 2017 and at december 31, 2016, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| goodwill | 718,000 | 718,003 | 718,000 | 718,000 | 718,000 | 718,003 | 718,000 | |||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 are designated at march 31, 2017 and december 31, 2016; 12,179 and 12,780 shares issued and outstanding at march 31, 2017 and at december 31, 2016, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b warrant liability | 865,000 | 3,851,000 | 11,025,000 | 14,180,000 | 17,438,731 | |||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 10,000 shares designated; zero and 4,555 issued and outstanding at december 31, 2016 and december 31, 2015, respectively. liquidation value of zero. | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 and zero shares designated at december 31, 2016 and december 31, 2015, respectively; 12,780 and zero shares issued and outstanding at december 31, 2016 and at december 31, 2015, respectively. liquidation value of zero. | 13 | |||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 10,000 shares designated; zero and 4,555 issued and outstanding at september 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 13,780 and zero shares designated at september 30, 2016 and december 31, 2015, respectively; 13,780 and zero shares issued and outstanding at september 30, 2016 and at december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 40,000 shares authorized, 7,780 and 4,555 issued and outstanding at june 30, 2016 and december 31, 2015, respectively. | ||||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 40,000 shares authorized, 8,335 and 4,555 issued and outstanding at march 31, 2016 and december 31, 2015, respectively. | ||||||||||||||||||||||||||||||||||||||||||||
| line of credit and accrued interest | 101,529 | |||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 40,000 shares authorized, 4,555 and 0 shares issued and outstanding at december 31, 2015 and december 31, 2014, respectively. | 5 | |||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||
| total long-term liabilities | 2,551,000 | 3,053,000 | 20,311,000 | |||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | -1,291,000 | -7,632,000 | -11,303,000 | -10,332,591 | -42,378,000 | |||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ deficit | 7,288,000 | 8,770,000 | 10,067,000 | 8,395,925 | 1,696,000 | |||||||||||||||||||||||||||||||||||||||
| government grant revenue | 155,000 | 65,000 | ||||||||||||||||||||||||||||||||||||||||||
| product revenue | 92,000 | 32,000 | ||||||||||||||||||||||||||||||||||||||||||
| total revenue | 247,000 | 97,000 | ||||||||||||||||||||||||||||||||||||||||||
| cost of product revenue | 56,000 | 22,000 | ||||||||||||||||||||||||||||||||||||||||||
| gross profit | 191,000 | 75,000 | 4,000 | |||||||||||||||||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||||||
| research and development | 1,193,000 | 1,181,000 | 878,000 | 2,242,216 | 717,000 | |||||||||||||||||||||||||||||||||||||||
| sales and marketing | 467,000 | 506,000 | 260,000 | 252,359 | 84,000 | |||||||||||||||||||||||||||||||||||||||
| general and administrative | 1,714,000 | 1,432,000 | 1,292,000 | 2,665,154 | 522,000 | |||||||||||||||||||||||||||||||||||||||
| total expenses | 3,374,000 | 3,119,000 | 2,430,000 | 5,159,729 | 1,323,000 | |||||||||||||||||||||||||||||||||||||||
| operating income | -3,183,000 | -3,044,000 | -2,426,000 | -5,159,729 | -1,323,000 | |||||||||||||||||||||||||||||||||||||||
| interest and other income | ||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -4,130,394 | |||||||||||||||||||||||||||||||||||||||||||
| change in fair value of warrants liabilities | 73,000 | 4,925,000 | -6,174,000 | |||||||||||||||||||||||||||||||||||||||||
| other income | -183,000 | 4,925,000 | -4,585,475 | -318,000 | ||||||||||||||||||||||||||||||||||||||||
| inducement charge for series c warrants | -3,050,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income | -3,293,000 | 1,881,000 | -11,651,000 | -13,874,513 | ||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -330 | -1,670 | -10.92 | -4,470 | ||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding used to calculate basic and diluted net income per common share | 10,040,079,000 | 6,965,483,000 | 1,270,033 | 535,685,000 | ||||||||||||||||||||||||||||||||||||||||
| patent | 562,000 | |||||||||||||||||||||||||||||||||||||||||||
| common stock issuable | 112,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||
| basic | 250 | |||||||||||||||||||||||||||||||||||||||||||
| diluted | 250 | |||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding used to calculate net income per common share: | ||||||||||||||||||||||||||||||||||||||||||||
| revenue | 22,000 | |||||||||||||||||||||||||||||||||||||||||||
| cost of revenue | 18,000 | |||||||||||||||||||||||||||||||||||||||||||
| interest | -1,000 | -752,000 | ||||||||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||
| convertible promissory notes and accrued interest | ||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock warrant liability | 3,066,000 | |||||||||||||||||||||||||||||||||||||||||||
| commitments | ||||||||||||||||||||||||||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 40,000 shares authorized, 0 and 31,250 shares issued and outstanding at december 31, 2014 and december 31, 2013, respectively; | ||||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, 320,000 shares authorized, 0 and 119,140 shares issued and outstanding at december 31, 2014 and december 31, 2013, respectively; | ||||||||||||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, 1,500,000 shares authorized, 0 and 715,039 shares issued and outstanding at december 31, 2014 and december 31, 2013, respectively; | ||||||||||||||||||||||||||||||||||||||||||||
| interest income | 1,085 | |||||||||||||||||||||||||||||||||||||||||||
| deferred offering costs | 1,353,000 | |||||||||||||||||||||||||||||||||||||||||||
| accrued liabilities | 358,000 | |||||||||||||||||||||||||||||||||||||||||||
| convertible promissory notes and accrued interest, net of discounts | 15,604,000 | |||||||||||||||||||||||||||||||||||||||||||
| series a convertible preferred stock, 0.001 par value, 40,000 shares authorized, 31,250 shares issued and outstanding at december 31, 2013 and september 30, 2014; | 1,500,000 | |||||||||||||||||||||||||||||||||||||||||||
| series b convertible preferred stock, 0.001 par value, 320,000 shares authorized, 119,140 shares issued and outstanding at december 31, 2013 and september 30, 2014; | 6,863,000 | |||||||||||||||||||||||||||||||||||||||||||
| series c convertible preferred stock, 0.001 par value, 1,500,000 shares authorized, 715,039 shares issued and outstanding at december 31, 2013 and september 30, 2014; | 15,445,000 | |||||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -2,393,000 |
We provide you with 20 years of balance sheets for Soleno Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Soleno Therapeutics. Explore the full financial landscape of Soleno Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Soleno Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.